Business Wire - July 21, 2003

The three licensed compounds are being investigated to treat a variety of diseases including cancer, AIDS, and acute inflammatory conditions such as stroke. Through this agreement, Crimson has obtained exclusive rights to develop and market the licensed compounds in China, Korea, Hong Kong, Taiwan, Singapore, and other countries and regions in Southeast Asia.

In addition to its two anti-cancer compounds, which have been highly active against tumor cells both in vitro and in vivo, Octamer has also developed a compound that represents a new class of therapeutic agents directed against AIDS. Octamer has completed pre-clinical studies on this anti-AIDS therapeutic and received Investigative New Drug (IND) approval from the U.S. FDA for oral administration of the compound in initial human trials. Jeffrey Price, Chairman and CEO of Octamer, stated today, "We believe this deal is a good match between Octamer and Crimson. The alliance can help us gain proof-of-concept and early market access through a regional player like Crimson in an efficient and economical fashion."

"This is the first in a series of licensing opportunities we have been engaged in," said Crimson's COO Sam Lou. "We are quickly building up our development pipeline through licensing and co-development collaborations worldwide. Our team in Shanghai is excited to take on these projects to address the needs in many areas in Asia, such as liver disease, diabetes, infectious diseases, cancers and aging." Yuanyi Lao, Crimson's CEO, remarked, "Crimson's global strategy creates partnership synergies for both regional and global pharmaceutical businesses. We can address the rising demand for novel therapeutics in high-growth Asian countries and at the same time provide our global partners access to an immense market potential."

About Crimson (www.crimsonpharma.com)

Crimson is a privately held biopharmaceutical company focused on developing and commercializing novel therapeutics in the Asia Pacific region to address unmet medical and economic needs. The Company has operations in Hong Kong, China, and the U.S. and specializes in advancing drug candidates from pre-clinical studies through clinical trials to reach the market in an accelerated development process.

CONTACT: Crimson

Vivian Lao, 201-585-0011

info@crimsonpharma.com

SOURCE: Crimson

030721
BW030707

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .